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Carcinoids are the most common endocrine tumors of the 
gastroenteropancreatic axis. It is now recognized that carci- 
noids share a number of histologic, ultrastructural, and bio- 
chemical features with other endocrinologically-active tumors 
and they are considered by many authorities to be part of the 
APUD (amine precursor uptake and decarboxylation) system of 
cells [1]. 
Carcinoid tumors arise from a multipotential primitive stem 
cell and are frequently classified according to their anatomic 
distribution and differing patterns of secretory behavior [2]. 
Midgut carcinoid tumors arise from the jejunum, ileum, and 
right colon, are argentaffin positive, and have a high seroton[n 
(5-HT) content. Unlike foregut carcinoids (bronchus, stomach, 
duodenum, and pancreas), midgut tumors generally do not 
secrete 5-hydroxytryptophan (5-HTP) or adrenocorticotropic 
hormone (ACTH) and rarely metastasize to bone. They can be 
easily distinguished histocytochemically from hindgut carci- 
noids because the latter do not contain serotonin and, therefore, 
stain argentaffin-negative. 
Midgut carcinoids tend to be relatively slow-growing and may 
go undiagnosed for many years. Once the tumor has grown 
transmurally into the mesentery, it appears to evoke an intense 
desmoplastic or fibroplastic reaction causing contraction and 
adherence of adjacent bowel loops with resulting partial or 
complete intestinal obstruction. Ischemic enteritis and intesti- 
nal gangrene may also result from vascular compromise due to 
mesenteric fibroplasia or from periadventitial hyperelastosis 
leading to the development of occlusive changes in small to 
moderate-sized mesenteric arteries [3]. Many of these patients 
will present with longstanding premonitory symptoms of inter- 
mittent abdominal pain, diarrhea, and unexplained weight loss. 
Prognosis appears to be determined largely by the extent of 
tumor involvement with reported 5-year survival rates of 94% 
for localized disease, 64% with regional lymph node involve- 
ment, and 18% with distant metastases [4]. Because of the 
indolent behavior of  these tumors, surgical palliation is war- 
ranted in patients with symptomatic bowel obstruction or 
ischemia, even in the presence of extraintestinal disease. Five- 
year survival rates of 20% and 38%, respectively, have been 
reported for "operable" patients with hepatic and regional 
lymph node metastases [5]. Postoperative chemotherapy may 
provide substantial albeit temporary palliation. 
Midgut carcinoids secrete a number of neuropeptides that 
have been implicated in the pathogenesis of "carcinoid syn- 
drome." Serotonin is thought to be the primary peptide respon- 
sible for diarrhea and may be an important cause of flushing as 
well as extraintestinal manifestations such as arthropathy, heart 
disease, and retroperitoneal fibrosis [6]. Histamine and, to a 
lesser extent, substance P, prostaglandins, and neuropeptide K 
have also been implicated in the clinical manifestations of 
carcinoid tumors [7] 
The majority of patients with midgut carcinoids develop 
carcinoid syndrome only in the presence of hepatic metastases 
and are rarely curable by surgery. Resection of hepatic metas- 
tases has been successful in carefully selected patients with 
severe carcinoid-induced diarrhea and flushing but should only 
be considered when symptoms are unresponsive to conven- 
tional chemotherapeutic agents [8]. Unfortunately, eventual 
relapse and tachyphylaxis to the drugs is frequently encoun- 
tered. More recently, suppression with long-acting somato- 
statin analogue (octreotide) was evaluated in a variety of 
neuroendocrine tumors including carcinoid. In one recent study 
of octreotide in 14 patients with biochemical and clinical 
evidence of carcinoid syndrome, symptoms of flushing, diar- 
rhea, and wheezing were controlled in the majority of patients, 
but the drug failed to suppress biochemical markers or tumor 
growth [7]. Despite failure to slow tumor progression, oc- 
treotide may provide excellent palliation of symptoms with 
relatively few adverse effects. 
The authors summarize a 10-year surgical experience in 5i 
patients with midgut carcinoids, 26 (51%) of whom had objec- 
tive evidence of carcinoid syndrome. Thirty-one patients (61%) 
had extensive mesenteric fibroplasia or nodal involvement that 
precluded radical resection and underwent surgical "debulk- 
ing" or intestinal bypass procedures. Only 6 patients with 
hepatic involvement were suitable candidates for resection or 
enucleation. Although survivors were followed for a mean of 
2.8 years, the authors did not describe the effects of surgery on 
the frequency and severity of preoperative symptoms. Since the 
majority of patients were given postoperative medical therapy, 
the usefulness of surgery per se cannot be evaluated. 
Surgery has a potentially important role in patients with 
mid-gut carcinoids, but should be viewed as one arm of a 
multimodality treatment regimen. Curative resection is unusual 
but should be attempted in all patients with disease limited to 
the bowel wall and adjacent mesentery. Surgical palliation 
should always he considered in patients with symptoms of  
bowel obstruction or ischemia, even in the presence of nodal or 
hepatic metastases. Similarly, resection of  bulky mesenteric, 
nodal, or hepatic metastases may be useful in carefully-selected 
patients with symptoms of carcinoid syndrome that prove 
refractory to medical management or arterial embolization [9]. 
Postoperative treatment with chemotherapeutic agents and 
hormonal suppressants may provide useful palliation, but 
should be withheld until the effects of surgery have been fully 
evaluated. 
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